Last reviewed · How we verify
Crushed ticagrelor, morphine,metoclopramide
This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and metoclopramide to enhance gastric motility and reduce nausea.
This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and metoclopramide to enhance gastric motility and reduce nausea. Used for Acute coronary syndrome with associated pain and nausea.
At a glance
| Generic name | Crushed ticagrelor, morphine,metoclopramide |
|---|---|
| Also known as | Brilique |
| Sponsor | Collegium Medicum w Bydgoszczy |
| Drug class | Antiplatelet agent + opioid analgesic + antiemetic (combination therapy) |
| Target | P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Acute Coronary Syndrome with pain management |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 receptor antagonist that prevents platelet activation and aggregation, reducing thrombotic events in acute coronary syndromes. Morphine is an opioid agonist providing analgesia and anxiolysis. Metoclopramide is a dopamine antagonist that increases gastric contractions and blocks chemoreceptor-mediated nausea, commonly used to counteract opioid-induced gastrointestinal effects and improve drug absorption.
Approved indications
- Acute coronary syndrome with associated pain and nausea
Common side effects
- Bleeding
- Bradycardia
- Respiratory depression
- Constipation
- Tardive dyskinesia (metoclopramide)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: